TAYSHA GENE THERAPIES INC (TSHA)
US8776191061 - Common Stock
TSHA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 569 industry peers in the Biotechnology industry. TSHA may be in some trouble as it scores bad on both profitability and health. TSHA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
TSHA had positive earnings in the past year.
TSHA had a negative operating cash flow in the past year.
In the past 5 years TSHA always reported negative net income.
In the past 5 years TSHA always reported negative operating cash flow.
1.2 Ratios
TSHA's Return On Assets of -12.64% is amongst the best of the industry. TSHA outperforms 86.10% of its industry peers.
With an excellent Return On Equity value of -25.65%, TSHA belongs to the best of the industry, outperforming 82.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.64% | ||
| ROE | -25.65% | ||
| ROIC | N/A |
ROA(3y)-92.53%
ROA(5y)N/A
ROE(3y)-6259.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TSHA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TSHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
TSHA has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, TSHA has an improved debt to assets ratio.
2.2 Solvency
TSHA has an Altman-Z score of -2.18. This is a bad value and indicates that TSHA is not financially healthy and even has some risk of bankruptcy.
TSHA has a Altman-Z score of -2.18. This is comparable to the rest of the industry: TSHA outperforms 52.41% of its industry peers.
TSHA has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.48, TSHA is not doing good in the industry: 73.62% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.18 |
ROIC/WACCN/A
WACC10.73%
2.3 Liquidity
TSHA has a Current Ratio of 5.51. This indicates that TSHA is financially healthy and has no problem in meeting its short term obligations.
TSHA has a Current ratio of 5.51. This is comparable to the rest of the industry: TSHA outperforms 59.00% of its industry peers.
A Quick Ratio of 5.51 indicates that TSHA has no problem at all paying its short term obligations.
TSHA has a Quick ratio (5.51) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.51 | ||
| Quick Ratio | 5.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 156.64% over the past year.
TSHA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -30.95%.
EPS 1Y (TTM)156.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.77%
Revenue 1Y (TTM)-30.95%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-62.28%
3.2 Future
The Earnings Per Share is expected to decrease by -34.21% on average over the next years. This is quite bad
Based on estimates for the next years, TSHA will show a very strong growth in Revenue. The Revenue will grow by 60.28% on average per year.
EPS Next Y-402.55%
EPS Next 2Y-129.95%
EPS Next 3Y-76.17%
EPS Next 5Y-34.21%
Revenue Next Year-42.23%
Revenue Next 2Y-39.89%
Revenue Next 3Y-28.99%
Revenue Next 5Y60.28%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 3.86, which indicates a rather cheap valuation of TSHA.
Compared to the rest of the industry, the Price/Earnings ratio of TSHA indicates a rather cheap valuation: TSHA is cheaper than 99.47% of the companies listed in the same industry.
TSHA's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 29.20.
TSHA is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.86 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as TSHA's earnings are expected to decrease with -76.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-129.95%
EPS Next 3Y-76.17%
5. Dividend
5.1 Amount
TSHA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TAYSHA GENE THERAPIES INC
NASDAQ:TSHA (11/22/2024, 8:09:43 PM)
After market: 2.47 0 (0%)2.47
+0.29 (+13.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap506.20M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.86 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.64% | ||
| ROE | -25.65% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.51 | ||
| Quick Ratio | 5.51 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)156.64%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-402.55%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-30.95%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y